AURELIA ONLINE
AURELIA ONLINE
GLP-1 MEDICAL WEIGHT CARE
Mounjaro Before Surgery, Anesthesia, or Endoscopy / Mounjaro / Medical weight care

Mounjaro Before Surgery, Anesthesia, or Endoscopy: What to Tell Your Doctor

It is okay to ask before deciding on your own.

Side effects, dose changes, pregnancy/contraception, surgery, severe abdominal pain, or poor intake may require individualized medical review.

Mounjaro Before Surgery, Anesthesia, or Endoscopy: What to Tell Your DoctorAURELIA ONLINEChiaroクリニックSelf-pay care

A practical guide to Mounjaro before surgery, anesthesia, sedation, and endoscopy: delayed gastric emptying, aspiration risk, perioperative guidance, and pre-procedure communication.

※This article is for general education. Diagnosis, prescription, dose adjustment, stopping, or restarting treatment must be decided by a physician.

Contents
How to use this article

This article organizes a common patient concern using product information, clinical literature, and practical consultation points.

Check first

Seek advice early if symptoms are severe, dehydration is possible, pregnancy is possible, surgery is planned, or other medicines are used.

Conclusion: always tell the surgical/anesthesia/endoscopy team that you use Mounjaro

Mounjaro delays gastric emptying. Even with fasting, residual gastric contents may be a concern. Before surgery, general anesthesia, deep sedation, endoscopy, colonoscopy, dental anesthesia, or procedures, tell the team your dose, last injection date, whether you recently escalated, and whether you have GI symptoms.

ItemApproximate numberHow to interpret
半減期 / Half-life約5日週1回投与の背景。
高リスク開始直後・増量直後胃腸症状がある時は特に申告。
対策術前食事調整等最終判断は手術・麻酔側。
Risk/attention level image
75Recent start80Escalation90GI symptoms30Stable

How perioperative guidance has evolved

Recent multi-society guidance emphasizes individualized risk assessment rather than automatic discontinuation for everyone. Pre-procedure diet modification, anesthesia plan adjustment, or gastric-content assessment may be considered.

Numbers vary by patient background, trial design, dose, and concomitant medicines. Your risk should be interpreted using symptoms, dose, history, and other medicines.

Common misunderstanding

When symptoms appear, some patients immediately assume the medicine is unsuitable, while others try to tolerate everything because the symptoms are common. Both reactions can be unsafe. It is better to separate mild discomfort from symptoms that interfere with daily life, dehydration, low glucose, pregnancy-related concerns, or abdominal emergencies.

Notes that help consultation

Clinicians can judge more accurately when they know the last injection date, current dose, treatment week, recent escalation, food intake, fluid intake, bowel movements, weight change, exercise, alcohol, medical history, and other medicines. Insulin, sulfonylureas, diuretics, blood pressure medicines, oral contraceptives, and anticoagulants can change the interpretation.

Lifestyle adjustment

The goal is not simply to eat as little as possible. Even with reduced appetite, patients need protein, fluids, tolerable carbohydrates, bowel regularity, sleep, and safe movement. When symptoms appear, safety and continuation are more important than faster weight loss.

When to seek advice

Mild symptoms with good fluid intake and normal daily function may improve with meal and hydration adjustments. Severe pain, repeated vomiting, fever, confusion, dehydration, pregnancy possibility, upcoming surgery, or a desire to change dose should prompt medical review.

FAQ

Q. Can I decide based only on this article?

No. This is general information. Strong symptoms, pregnancy, surgery, medicines, hypoglycemia, or abdominal pain require medical review.

Q. Can I reduce or skip the dose myself?

Avoid changing the dose on your own. If side effects occur, discuss delay, dose reduction, or restart with a physician.

Q. Can I ask via LINE before booking?

Yes. You can ask via LINE before booking.

Related pages

References

  1. Eli Lilly and Company. MOUNJARO US Prescribing Information / Medication Guide.
  2. European Medicines Agency. Mounjaro EPAR Product Information.
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
  4. Kindel TL, et al. Multi-society clinical practice guidance for safe perioperative use of GLP-1 receptor agonists. 2024.
  5. Skelley JW, et al. Impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception. 2024.

Numbers are general information based on trials and product information. Individual risk and action should be determined in consultation.

Need to apply this to your situation?

You can discuss symptoms, dose, weight change, intake, other medicines, and a safe continuation plan.

Mounjaro consultationCheck side effects, dose, and continuation online
Book